Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05340764 · ClinicalTrials.gov registry record · Phase 4
Safety of Reduced Infliximab Infusion Time
A Phase 4 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
NCT05340764 is a Phase 4 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 96 participants.
The verdict
NCT05340764, a Phase 4 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
Study Summary
Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate. The investigators would like to see if the infusion can be given over 1 hour. The investigators expect that increasing the rate of infusion WILL NOT lead to an increase in infusion reactions and will be just as safe and effective as the standard 2 hours dose.
Interventions
- DRUG Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2023-05-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05340764
The ClinicalTrials.gov registry entry for NCT05340764 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infliximab is the first listed.
NCT05340764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05340764 about?
NCT05340764 is a clinical study titled "Safety of Reduced Infliximab Infusion Time". Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate. The investigators would like to see if the infusion can be given over 1 hour....
What is the current status of trial NCT05340764?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2020-08-01. Estimated completion is 2023-05-04.
What interventions are being tested in trial NCT05340764?
The interventions under investigation include: Infliximab (DRUG).
Who is sponsoring clinical trial NCT05340764?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.